Market Research Report
Global Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028
|Published by||Data Bridge Market Research Private Limited||Product code||991584|
|Published||Content info||292 Pages
Delivery time: 1-2 business days
|Global Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028|
|Published: January 1, 2021||Content info: 292 Pages||
Global pharmacogenetic testing in psychiatry/depression market is projected to register a substantial CAGR of 9.4% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.
Global Pharmacogenetic Testing In Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-The-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-To-Consumer Services and Mail-Order Pharmacies), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa, Brazil and Rest of South America) Industry Trends and Forecast to 2028.